~~<i id='1698F47D96'><strike id='1698F47D96'><tt id='1698F47D96'><pre id='1698F47D96'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：focus 2025-10-06 11:31:15 - browse：8

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Sophia Smith scores twice for US in in 3

knowledge

explore

knowledge

hotspot

knowledge

hotspot

AnMRIscanoftheprostate.MichaelOhliger/UCSFMendiagnosedwithearlyprostatecancercansafelychooseactivemo

WSS

The pink breast cancer awareness ribbon needs a redesign

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Telehealth options flood the market as retailers push virtual care

Eli Lilly to pay $200M for Beam’s stake in gene

The pink breast cancer awareness ribbon needs a redesign

Novartis develops a rapidly manufactured CAR

hotspot

entertainment

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Meta's Zuckerberg and Chan on track to put $50 billion into science

Hollywood unions extend contract negotiations for actors

Paying for Covid pills will soon shift to insurers

Walensky prepares to leave CDC — and Congress — behind

The FDA weighs the risks of candy

Activists slam private health insurers over coverage restrictions

What Henrietta Lacks's story taught me about my role as a doctor

Medical leaders decry Supreme Court decision on affirmative action

Paying for Covid pills will soon shift to insurers

explore

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

First Opinion Podcast: How to protect health care in times of war

Readout Newsletter: What happened with Sarepta's Duchenne data

The FDA weighs the risks of candy

FAMU bans football players from facility after release of rap video shot in team's locker room

Burning questions about Delta and the next phase of the Covid pandemic

knowledge

hotspot

knowledge

hotspot